Healing Biotechnology Announces Good Laboratory Practice (GLP) Toxicology Studies With Metformin-Based Eye Drops Formulations For Macular Degeneration Treatment

Healing Biotechnology Announces Good Laboratory Practice (GLP) Toxicology Studies With Metformin-Based Eye Drops Formulations For Macular Degeneration Treatment

Healing Biotechnology, Inc.

National Institute of the Eyes (IN THE) to Collaborate with Curative Biotechnology under Cooperative Research and Development Agreement (CRADA)

Boca Raton, FL, May 03, 2022 (GLOBE NEWSWIRE) – Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or “Company”), a developing biomedical company focused on novel treatments for diseases rare and conditions, announced today that the company has switched to the Good Laboratory Practice (GLP) toxicology study.

The present study is designed to evaluate the tolerability, pharmacokinetics and any local or systemic toxicity of reformulated metformin when administered topically by ocular route. The study will also evaluate its distribution in ocular tissue.

The Toxicology Study of Good Laboratory Practice (GLP) is a requirement for submission to the FDA Investigational New Drug (IND).

Ocular tolerance includes dosing observations, general clinical observations twice daily (assessment of behavior / clinical signs with particular attention to the eyes), ophthalmic examinations by a Board certified veterinary ophthalmologist according to the modified Hackett-McDonald score scale, and ocular histopathology.

Under a cooperative research and development (CRADA) agreement, the National Eye Institute (NEI) and Curative Biotechnology, Inc. will collaborate to evaluate Curative’s proprietary ocular metformin formulation in clinical trials for the treatment of macular degeneration related to intermediate and advanced age (AMD) disease.

Future press releases on curative biotechnology and industry updates

Interested investors and shareholders will receive press releases and industry updates by sending an email to ir@curativebiotech.com.

Information on Curative Biotechnology, Inc. http://curativebiotech.com

Curative Biotechnology, Inc. (Curative Biotech) is a developing biomedical company focused on novel therapies for rare diseases. The company is focused on the identification, acquisition and development of disease-modifying therapeutic drug candidates with a focus on rare disease indications. Curative Biotech has ongoing programs in three different therapeutic areas: infectious diseases, neuro oncology and degenerative diseases of the eye. The company’s pipeline includes IMT504, CURB906, and metformin reformulation. IMT504 is a novel immune therapy for the treatment of rabies and an adjuvant for vaccines, CURB906 is a fully humanized CD56 monoclonal antibody that delivers a conjugated cytotoxic drug directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the cancer. The reformulation of metformin is aimed at the treatment of intermediate and advanced age-related macular degeneration disease (AMD).

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CUBT is not yet generating revenue. Although the forward-looking statements contained in this release reflect the good faith judgment of management, the forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those discussed in these forward-looking statements, including including but not limited to our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow and general economic conditions. Readers are encouraged to carefully review and consider the various disclosures we provide in our reports filed from time to time with OTC Markets which attempt to warn interested parties of the risks and factors that may affect our business, financial condition, results of operations and liquidity flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results could vary materially from those expected or anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We undertake no obligation to update any forward-looking statements to reflect any event or circumstance that may occur after the date of this release.

Steve Chizzik
Investor Relations
Healing Biotechnology (CUBT)

Leave a Comment

Your email address will not be published.